This live webinar is scheduled in Eastern Time (ET). Convert to your time zone
It will also be available on demand through May 31, 2025, following the live webinar.
Description
This webinar will focus on the harmonization status of commonly used tumor markers—α-fetoprotein (AFP), prostate specific antigen (PSA), carcinoembryonic antigen (CEA), cancer antigen (CA)125, CA15-3 and CA19-9—which are important diagnostic tools in cancer care. For their optimal clinical use, including application of general clinical decision limits, appropriate harmonization status of the measurement procedures is essential. The current status of harmonization will be discussed using data from six international external quality assessment (EQA) scheme providers. The presenters will describe how EQA data can be used to establish the current status of harmonization, including consideration of the importance of commutability in the context of EQA sample distribution. The current status of harmonization for each of the tumor markers will be described, and the clinical and laboratory implications of this discussed. Priority areas for future harmonization/standardization of tumor markers will be identified.
The presentation will be followed by a live Q&A with the speaker.
Read the article in Clinical Chemistry.
Target Audience
This activity is designed for physicians, lab supervisors, lab directors (and/or assistant directors), lab managers (supervisory and/or non-supervisory), medical technologists, point-of-care coordinators, pathologists, toxicologists, fellows, residents, in-training individuals, and other laboratory professionals overseeing/conducting within this topic.
Learning Objectives
At the end of this session, participants will be able to:
- Describe the current harmonization status of the commonly measure tumor markers α-fetoprotein (AFP), prostate specific antigen (PSA), carcinoembryonic antigen (CEA), cancer antigen (CA)125, CA15-3 and CA19-9.
- Describe how external quality assessment scheme data can be used to determine harmonization status, and the limitations of this.
- Describe the clinical and laboratory implications of the current harmonization status of tumor markers.
Faculty
Moderator
Ian Young, BSc, MD, FRCP, FRCPath
Professor of Medicine and Consultant Chemical Pathologist
Queen's University Belfast / Belfast Health and Social Care Trust
Chief Scientific Advisor / Director of Research and Development
Department of Health, Northern Ireland Government
Belfast, United Kingdom
Speaker
Huub van Rossum, EuSpLM, PhD
Specialist in Laboratory Medicine
Netherlands Cancer Institute
Amsterdam, the Netherlands
Disclosures and Statement of Independence
The Association for Diagnostics & Laboratory Medicine (formerly AACC) is dedicated to ensuring balance, independence, objectivity, and scientific rigor in all educational activities. All participating planning committee members and faculty are required to disclose to the program audience any financial relationships related to the subject matter of this program. Disclosure information is reviewed in advance in order to manage and resolve any possible conflicts of interest. The intent of this disclosure is to provide participants with information on which they can make their own judgments.
The following faculty reported financial relationships:
- Huub van Rossum, EuSpLM, PhD
- Honorarium/Expenses: Huvaros B.V., SelfSafeSure Blood Collections B.V.
- Grant/Research Support: Roche Diagnostics, Health Holland, Stichting Treatmeds
- Board/Committee/Membership/Advisory Board: ISOBM, Huvaros B.V., SelfSafeSure Blood Collections B.V.
- Stocks/Bonds: Huvaros B.V., SelfSafeSure Blood Collections B.V.
- Ownership: Huvaros B.V.
The following faculty reported no financial relationships:
- Ian Young, BSc, MD, FRCP, FRCPath
Content Validity
All recommendations involving clinical medicine are based on evidence accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients; AND/OR all scientific research referred to or reported in support or justification of a patient care recommendation conforms to generally accepted standards of experimental design, data collection, and analysis.
Accreditation Statement
This activity will be submitted for approval of up to 1.0 ACCENT® continuing education credits.
Successful Completion Statement
Verification of Participation certificates are provided to registered participants based on completion of the activity, in its entirety, and the activity evaluation. For questions regarding continuing education, please email [email protected].